Panels are grouped analyzes for monitoring the general condition of the organism or guidelines for a doctor to make a right diagnosis.
By choosing the appropriate panel, the TOTAL PRICE OF THE ANALYSIS INCLUDED is more favorable!
Anemia is a condition in which there is a deficiency of red cells or of hemoglobin in the blood, which is in charge of binding oxygen to itself, which it then transports to all tissues and organs, with the aim of their smooth functioning. Disorders can be acute or chronic and can have different origins.
The most common cause of anemia is a lack of Iron, which can be the result of poor nutrition, disorders in the digestive tract, blood loss during menstruation or long-term bleeding from the nose or hemorrhoids, after surgical interventions or some chronic diseases.
The most common symptoms of anemia are: fatigue, dizziness, weakness, headache, pale skin, nausea, shortness of breath, chest pain, rapid heartbeat, cold hands and feet, etc.
The analyzes included in this panel give a good insight into the state of the red blood cell lineage.
The optimal time to repeat this analysis is 3 months, which represents the time for which all red blood cells are replaced by the new ones.
By comparing the results of the analyzes from this panel obtained in the space of 3 months, a change in the condition can be reliably determined.
The panel includes the following analyses: blood count, CRP, iron, TIBC, UIBC, transferrin saturation and ferritin.
Preparation for analysis:
Blood sampling is recommended in the morning from 7-9am. 24 hours before sampling, avoid intense physical activity. It is necessary to pass 12 hours since the last meal. 1 hour before sampling without a cigarette. A few days before the sampling, you should not take regular therapy with drugs or supplements for the treatment of anemia.Expect results within 24 hours.
Autoimmune diseases occur when the immune system does not function well and mistakenly attacks its own organism, as if it were foreign. In such a state, antibodies are created against one's own cells.
The trend of autoimmune diseases is constantly increasing, and the diagnosis itself is not simple.
The most common causes are: stress, viral and bacterial infections, drugs, heavy metals, but also genetic predisposition (hereditary factors).
The symptoms are various, but the most common are: malaise, fatigue, pain in muscles and joints, skin rash, change in skin color, etc.
For diseases of the autoimmune system, the most important thing is to detect them as soon as possible, in order to put them under control and prevent further progression.
With us, you can check the status of your autoimmune system through a panel of 7 analyses, expertly and carefully selected by experienced doctors.
We recommend the autoimmune panel especially to those who have had Covid!
Preparation for analysis: Take blood at any time during the day.
Expect results within 48 hours.
Menopause is a physiological state that occurs after the end of the reproductive period of every woman's life.
Menopause occurs after the period of perimenopause (a period of gradual loss of menstruation and decline in estrogen production), and after menopause comes post-menopause (a period in which a woman has been without menstruation for more than 12 consecutive months).
Often this change is accompanied by the appearance of harmless but very unpleasant complaints such as: sudden sweating, night sweats, depression, mood swings, anxiety, fatigue, dry skin, etc.
For all these reasons, many women turn to doctors for help. We believe that it is then useful to have the results of the analysis of the "Menopause" panel, which will enable the doctor to monitor changes in hormonal status and define the risk of cardiovascular diseases and osteoporosis, which women are particularly exposed to in post-menopause.
The panel includes the following analyses: FSH, LH, Estradiol, Vit. D, Folate and Homocysteine.
Preparation for analysis: A few days before giving blood for analysis, reduce the intake of food of animal origin.
Expect results within 24 hours.
If you have a genetic predisposition to developing diabetes or cardiovascular diseases, If you lead a fast and unhealthy life, with excessive commitment to work, with daily exposure to great stress, if you skip meals, often eat in fast food restaurants, etc.All these, represent triggers for the appearance of the most serious diseases and make our road to health longer and longer.
For this reason, WE RECOMMEND A METABOLIC PANEL - once a year, as a check of metabolic health parameters.
The panel consists of 9 carefully selected analyses, selected by a team of experienced doctors in order to quickly and accurately assess your metabolic status.
Preparation for analysis:
Blood sampling is recommended in the morning from 7-9am. 24 hours before sampling, avoid intense physical activity. It is necessary to pass 12 hours since the last meal. 1 hour before sampling without a cigarette. On the day of blood sampling, regular drug or supplement therapy should be taken after blood collection.Expect results within 24 hours.
Osteoporosis is a process that affects the bone system, usually around the age of fifty. The degree of expression depends on many internal and external factors, and the symptoms are mild and difficult to recognize except in the case of bone fractures, when they are observed on an X-ray. By then, osteoporosis is usually already advanced.
Factors that can contribute to the development of osteoporosis are: estrogen deficiency during perimenopause and menopause, calcium deficiency, insufficient physical activity, low vitamin D levels, long-term use of corticosteroids.
Therapy to slow the progression of osteoporosis is more effective when it is started as early as possible.
The key tool for establishing a diagnosis is the analyzes from this panel in combination with other specific diagnostic procedures.
Ignoring osteoporosis opens up space for severe bone injuries that can occur spontaneously. In old people, such conditions can be fatal.
The panel consists of the following analyses: vitamin D, calcium, inorganic phosphate, PTH, beta cross laps, osteocalcin.
Preparation for analysis: Taking vitamin D and calcium should be stopped a few days before giving blood for analysis.
Expect results within 24 hours.
The thyroid gland plays an important role in our body, because with its hormones it affects: growth, development, metabolism, heartbeat, sexual function, pregnancy maintenance, blood glucose level, body temperature, as well as Ca metabolism.
Analyzes from this panel show well the condition of this complex system and help to recognize mild disorders that give non-specific symptoms. More severe, late-recognized disorders of the functioning of the thyroid gland are most clearly observed in disorders of the heart.
Therefore, periodic control of thyroid gland function can contribute to maintaining health or reducing the consequences of changes to a minimum.
The panel includes the following analyses: TSH, FT4, anti Tg antibodies and anti TPO antibodies.
Analyzes of autoantibodies are significant in assessing the existence of an autoimmune disorder of the thyroid gland, which can be the main cause of thyroid gland dysfunction.
Preparation for analysis:
Blood sampling is recommended in the morning from 7-9am. 24 hours before sampling, avoid intense physical activity. It is necessary to pass 12 hours since the last meal. 1 hour before sampling without a cigarette. On the day of blood sampling, regular drug or supplement therapy should be taken after blood collection. A few days before giving blood for analysis, reduce the intake of black coffee.Expect results within 24 hours.
In order to prevent the disease or detect it early, we recommend the following analyses, at least once a year:
Complete examination of urine Urine culture KKS Sedimentation Glucose Urea Creatinine Uric acid Lipid status Iron Ferritin ALT, AST, ALP, GGT, Electrolytes (Na, K, Cl, Ca ion) TSH FT4 Total proteins Total and direct bilirubin PSA free and totalThe advantage of choosing panels is also reflected in the fact that their total price is more favorable than the sum of the same, individually selected analyses.
Preparation for analysis:
Blood sampling is recommended in the morning from 7-9am. 24 hours before sampling, avoid intense physical activity. It is necessary to pass 12 hours since the last meal. 1 hour before sampling without a cigarette. On the day of blood sampling, regular drug or supplement therapy should be taken after blood collection. In the shortest period (2 hours), bring a sample of the first morning urine (middle stream) in a sterile container. Minimum 3 days from prostate examination. Avoid ejaculation for at least 24 hours.Expect results within 24 hours.
In order to prevent the disease or detect it early, we advise all Ladies to undergo the following tests, at least once a year:
Complete examination of urine KKS Sedimentation Glucose Urea Creatinine Uric acid Lipid status Iron Ferritin ALT, AST, ALP, GGT, Electrolytes (Na, K, Cl, Ca ion) TSH FT4The advantage of choosing panels is also reflected in the fact that their total price is more favorable than the sum of the same, individually selected analyses
Preparation for analysis:
Blood sampling is recommended in the morning from 7-9am. 24 hours before sampling, avoid intense physical activity. It is necessary to pass 12 hours since the last meal. 1 hour before sampling without a cigarette. On the day of blood sampling, regular drug or supplement therapy should be taken after blood collection. In the shortest period (2 hours), bring a sample of the first morning urine (middle stream) in a sterile container.Expect results within 24 hours.
Lipid status in the blood is a very important analysis for assessing the status of the vascular system, treating atherosclerosis and evaluating the effect of therapy.
The results of the analyzes included in this panel will be useful for evaluating your body's ability to compensate for the tendency to create LDL cholesterol ("bad cholesterol") to a greater extent than desired, as well as your genetic predisposition to the occurrence of heart and cardiovascular diseases.
The panel includes the following analyses: triglycerides, cholesterol, HDL cholesterol, LDL cholesterol, risk factor, atherosclerosis and lipoprotein index.
The results of these analyzes will be an important guideline for your doctor in choosing an adequate therapy.
Preparation for analysis:
Blood sampling is recommended in the morning from 7-9am. 24 hours before sampling, avoid intense physical activity. It is necessary to pass 12 hours since the last meal. 1 hour before sampling without a cigarette. One week before sampling, avoid alcohol. On the day of blood sampling, regular drug or supplement therapy should be taken after blood collection.Expect results within 24 hours.
Prediabetes is a serious medical condition in which blood sugar levels are higher than normal, but not yet high enough to be diagnosed as Type 2 diabetes.
The causes of this condition can be various, and above all, they are: inadequate nutrition, hereditary factors, insufficient physical activity, smoking, body mass index greater than 25, polycyclic ovary syndrome, insulin resistance.
Symptoms can be silent signs, such as mild fatigue, increased need to urinate, increased appetite, weight gain, dry and thickened skin, accelerated hair loss, etc.
To avoid deeper complications that can lead to blockage of arteries, heart attack or stroke, etc. it is recommended to perform this panel in order to evaluate the potential tendency for a disorder of glucose metabolism.
The panel includes the following analyses: Glucose, Examination of the first morning urine, Glycated hemoglobin (HbA1c), Cholesterol, Triglycerides, HDL - cholesterol and LDL - cholesterol.
Preparation for analysis:
Blood sampling is recommended in the morning from 7-9am. 24 hours before sampling, avoid intense physical activity. It is necessary to pass 12 hours since the last meal. 1 hour before sampling without a cigarette. On the day of blood sampling, regular drug or supplement therapy should be taken after blood collection. In the shortest period (2 hours), bring a sample of the first morning urine (middle stream) in a sterile container.It is repeated in 3 months if the results are borderline.
Expect results within 24 hours.
PSA is a specific prostate tumor marker and its increased values can indicate prostate disease.
For a complete assessment of the PSA value in the blood, free PSA, total PSA and index free PSA/total PSA are determined.
For all men over 50 years of age, it is recommended to determine PSA once a year as a screening method.
People with a family history of prostate cancer are recommended to have a PSA test from the age of 40.
Preparation for analysis:
24 hours before sampling, avoid intense physical activity. Minimum 3 days from prostate examination. Analyzes should be done before prostate biopsy and cytoscopy. Avoid ejaculation for at least 24 hours. Avoid tight-fitting clothes and tight clothes.Expect results within 24 hours.
This group of analyzes includes hormones whose level changes during one menstrual cycle or during pregnancy. It is preferable that they be determined in terms and intervals defined in cooperation with the doctor, in order to ensure the maximum usability of the results.
Oral contraceptives significantly affect the level of reproductive hormones in the circulation, which should be taken into account when interpreting the results.
It is also important that the determination cycle be performed in the same laboratory, because often the results obtained with reagents from different manufacturers are not comparable.
The panel includes the following analyses: LH, FSH, estradiol, testosterone, prolactin and progesterone.
Preparation for analysis: A few days before giving blood for analysis, reduce the intake of food of animal origin.
Expect results within 24 hours.
Weakening of kidney function is often a long-term process, and it is very important to be noticed at the beginning so that therapy can start on time and give the best possible result. Characteristic symptoms associated with the mentioned findings (last several months) are: nausea, weight loss, swelling, weakness.
A renal function panel analysis gives a good insight into the condition of the kidneys.
Complete examination of urine KKS CRP Glucose Proteins Albumin Lipid status Electrolytes (Na, K, Ca total, Ca ion, Cl) Inorganic phosphates Urea Creatinine and eGFR AST, ALT, ALP Total and direct bilirubinPreparation for analysis:
Blood sampling is recommended in the morning from 7-9am. Avoid intense physical activity 48 hours before sampling. It is necessary to pass 12 hours since the last meal. 1 hour before sampling without a cigarette. On the day of blood sampling, regular drug or supplement therapy should be taken after blood collection.Expect results within 24 hours.
Molecular oncology diagnostics - Your genes speak, we translate.
Telomeres - Estimate biological age by measuring telomere length.
Oxidative stress - a recommendation for everyone who wants to know the chemical "identity card" of the organism.
Glutation - powerful weapon in the fight for longevity.
Chitotriosidase - faster and cheaper to reliable results.
We are excited to announce this new strategic partnership that combines the expertise and resources of both laboratories to deliver innovative healthcare solutions and improve care for cancer patients.
The collaboration between Genekor Medical SA and ADEA LAB aims to ensure access to quality healthcare services for all citizens. By combining their strengths in research, development and distribution, the two companies promise to drive positive change and have a lasting impact on the health and well-being of cancer patients in Serbia.
Hightlight:
Description: HerediGENE® is a diagnostic multigene test for hereditary cancer that analyzes 52 genes, 21 of which are related to homologous recombination (including BRCA 1/2). These genes are involved in the increased risk of breast, ovarian, prostate, colorectal and other hereditary cancers. It uses advanced next-generation sequencing (NGS) technology.
The test can be used as a means of prevention, providing the doctor with correct information regarding personalized treatment for the patient, or identifying family members predisposed to cancer.
Types of cancer: Breast, colorectal, prostate, pancreas, ovary, stomach, melanoma, thyroid, kidney, endometrium.
Cancer syndromes: Hereditary breast and ovarian cancer syndrome, Lynch syndrome, Cowden syndrome, Li-Fraumeni syndrome, Peutz-Jeghers syndrome, familial adenomatous polyposis, Von-Hippel Lindau syndrome, multiple endocrine neoplasia, others.
Possible results:
• A negative result indicates that no clinically significant mutation was identified.
• A positive result indicates that a pathogenic mutation has been identified and there is medical treatment based on international recommendations for carriers of that mutation.
• A variant of unknown significance (VUS) indicates that there are identified findings that have not been clarified based on the international literature with the data to date. Medical management is based on personal and family history.
• All breast cancer patients
• Individuals with any type of cancer at a young age
• Individuals with bilateral breast cancer and/or ovarian cancer
• Individuals with the same type of cancer occurring in close relatives, and the presence of cancer in several generations of the same family
• Individuals with rare tumors of any age
• Individuals with first-degree relatives who had cancer at a young age or have a known gene mutation
• Individuals who develop hundreds or thousands of polyps
• Men with breast cancer
Additional information: The results are useful for the entire family, as it is enough for a person to inherit a mutation from one parent to have an increased risk of developing cancer. Any individual whose parent is a carrier of the mutation has a 50% chance of inheriting the mutation. More distant relatives are also at risk of carrying the mutation.
Keep in mind that inherited predisposition syndromes can be associated with many different types of cancer. Therefore, a mutation found in a breast or ovarian cancer sample may be associated with an increased risk of pancreatic or prostate cancer.
Deadline for receiving the result: until 24 working days.
Description: The new prime DX® technology for molecular tumor profiling is compatible with both FFPE and PLASMA!
It is one of the most detailed, sensitive and specific tumor biology profiling tests, allowing doctors to plan effective cancer treatment for the patient, including targeted therapies, immunotherapy, chemotherapy, PARP inhibitors and clinical trial eligibility. It provides answers regarding the toxicity of chemotherapy drugs, such as 5-FU, irinotecan and others.
The test can be used in the following cases:
• Aggressive tumors without standard cancer treatment (e.g. pancreatic cancer)
• When the initial cancer treatment plan is complete, but more treatment options need to be considered
• Tumors of unknown primary origin
• Secondary treatment
• Rare tumors
• Tumors without an established “gold standard” for treatment
• Tumors with several available treatment options, where the doctor must decide which one will be most effective for a particular patient (such as lung cancer).
In addition, For a clear indication of the patient's immune response, allowing the physician to know if an immunotherapy plan would be beneficial and/or to create the most effective immunotherapy plan.
Why choose prime DX®?
Choosing the most appropriate cancer treatment: Proven to provide more actionable information than any other test. By analyzing 1,021 unique cancer genes and the immunotherapy biomarkers MSI, PD-L1, LOH (for ovarian cancer), HLA and TMB, the prime DX® test provides access to the largest amount of actionable information to date, providing the clearest indication to the physician of which targeted therapies will and will not benefit the patient, including immunotherapy, chemotherapy and PARP inhibitors.
Continuous support for the doctor and the patient from an experienced team. The prime DX® test procedure or any other test at Genekor Medical SA does not end with the notification of the results. The experienced customer service and scientific consulting teams work with the doctor and the patient throughout the process.
Highly accurate, sensitive and reliable technology: Based on advanced hybrid detector enrichment technology of targeted genomic regions, it also uses molecular trackers (UMI) for increased sensitivity in detecting somatic variants.
Results The prime DX® test results include a detailed explanation of all findings, including the following information:
• Molecular profiling of tumor tissue with details of specific gene mutations and interactive access to information related to the specific gene
• Recommended approved therapies and anti-cancer therapies that may be of great benefit to the specific patient with interactive access to clinical studies
• Proposed experimental anticancer therapies with interactive access to clinical trials
• Treatment with associated resistance that will not benefit the specific patient
• Suggestions for medications with documented indications
You can add the following immunohistochemical markers:
• PD-L1
• HER2 overexpression
• FRα for ovarian cancer
• Claudin 18.2 for adenocarcinoma of the stomach and gastroesophageal junction
Deadline for receiving the result: 18 working days
What type of sample is needed for the test?: Tumor block
Prime DX is an NGS panel of 1021 genes, of which 36 are HR genes
The test also includes:
• Immunotherapeutic biomarkers
• PARP inhibitors biomarkers
• IHC Biomarkers
Biomarkers included in test:
• TMB
• MSI
• HLA
• LOH
• PD-L1
• HER2
• FRα
• CLDN18.2
Agnostic markers:
• NTRK1, 2, 3
• RET Fusions
• BRAFV600E Mutation
• HER2 Amplification
Immunotherapy markers:
• TMB
• MSI
Description: The new prime DX® Liquid test consists of a panel of 1021 genes, analyzing the immunotherapy biomarkers TMB, MSI, HLA, which allows the treating physician to plan effective treatment, including immunotherapy, chemotherapy, PARP inhibitors and compatibility for participation in clinical trials.
In addition, prime DX® Liquid analyzes genes associated with genetic predisposition to cancer, thus providing information to the doctor about the likelihood of a hereditary cancer syndrome.
Recommended for the following cases:
• When there is not enough tissue or a recent biopsy
• If the tissue quality is poor (for example, too much bone in the sample)
• In metastatic and multifocal disease
• After treatment to check the patient's response
• If the patient relapses and needs molecular profiling without biopsy
Advantages of liquid biopsy:
• Non-invasive method (blood sampling)
• Possibility of sequential analyses – monitoring of disease progress
• Low failure rate (~3%) due to material incompatibility
• Better assessment of tumor genetic heterogeneity
Results: The prime DX® Liquid analysis results include a detailed explanation of all findings, including the following information:
• Molecular profiling of tumor tissue with details of specific gene mutations and interactive access to information related to the specific gene
• Recommended approved therapies and anti-cancer therapies that may be of great benefit to the specific patient with interactive access to clinical studies
• Proposed experimental anticancer therapies with interactive access to clinical trials
• Treatment with associated resistance that will not benefit the specific patient
• Suggestions for medications with documented indications
Deadline for receiving the result: 18 working days
Description: Revolutionary Precision Medicine: Dual Testing for Comprehensive Molecular Profiling. Prime DX® Combo enables simultaneous testing of FFPE (formalin-fixed paraffin-embedded tissue) and liquid biopsy samples.
Why choose simultaneous tissue and liquid biopsy testing?
• Faster turnaround time, allowing patients to receive their preferred treatment in a timely manner
• Increased diagnostic accuracy through increased mutation detection sensitivity, therefore reducing false negative results
Technical characteristics of the prime DX® Combo:
It is based on advanced technology using hybridization probes of targeted genomic regions. It uses molecular indicators (UMI) for increased sensitivity in detecting somatic variants. The technology has shown high reproducibility, sensitivity and specificity and has been adopted by leading oncology institutions around the world.
The test uses the Oncology Multi-Gene Variant Assay (GenePlus) - a qualitative in vitro diagnostic test (CE-IVD), detecting variants in 1021 tumor-associated genes and gene rearrangements/fusions in 38 genes.
Analyzes biomarkers of immunotherapy response, including:
• MSI (microsatellite instability)
• TMB (tumor mutation burden)
• HLA zygosity detection
• and biomarkers of chemotherapy response
MGI-DNBSEQ-G400 is a CE-IVD platform that allows for the simultaneous processing of multiple samples with high sensitivity and specificity, providing faster and more reliable results at a lower cost.
The following predictive immunohistochemical markers performed in our pathology laboratory can be added to PrimeDX®:
• PD-L1
• HER2 overexpression
• FRα for ovarian cancer
• Claudin 18.2 for adenocarcinoma of the stomach and gastroesophageal junction
Deadline for receiving the result: 18 working days
Description: Molecular testing for non-small cell lung cancer (NSCLC)
The ComPlit DX® multigene test provides important information about tumor biology and can lead to the identification of cancer-causing mutations, known as “driver mutations.” The result helps the treating physician and patient reach the most effective personalized treatment for non-small cell lung cancer (NSCLC). It can also be used for other types of solid tumors, including those with an unknown primary tumor.
Reasons to take the test:
• Determines the molecular profile of the tumor (gene mutations) and interactions between genes in cases of multiple mutations.
• Identifies drugs that target either the mutated gene(s) or the pathways in which they are involved.
• Identifies mutations associated with resistance to targeted therapies.
• Recommends treatments that are approved for the specific mutation but also suitable for a different tumor type and/or indicates treatments in clinical trials.
• Immunotherapeutic biomarkers: PD-L1
• IHC biomarkers: HER2
Deadline for receiving the result: 15-18 working days
What type of sample is needed for the test?
Tumor block
7 Gene rearrangements:
ALK, MET, NTRK1, NTRK2, NTRK3, RET, ROS1
Panel of 27 Gene Mutations:
AKT1, ALK, BRAF, CDKN2A, CTNNB1, DDR2, EGFR, ERBB2, FBXW7, FGFR1, FGFR2, FGFR3, HRAS, KEAP, KRAS, MAP2K1, MET, NOTCH1, NRAS, PIK3CA, POLE, PTEN, RET, SMAD4, SMARCA4, STK11, TP53
Description: The Com.pl.it DX® Colon multigene test includes gene mutations associated with colorectal cancer. The analysis of many of them is essential for designing a personalized treatment plan for patients.
How does the Com.Pl.it DX® test help in choosing the right treatment?
• Determines the molecular profile of the tumor (gene mutations) and interactions between genes in cases of multiple mutations.
• Identifies approved drugs targeting either the mutated genes or the pathways in which they are involved.
• Identifies mutations associated with resistance to targeted therapies.
• Recommends off-label or clinical trial therapies based on the molecular profile of the tumor. This may be especially important for patients who have failed standard treatments.
• Immunotherapeutic biomarkers: MSI
• Immunohistochemical Biomarkers (IHC): HER2
Deadline for receiving the result: 15 working days
Panel of 27 Gene Mutations:
AKT1, ALK, BRAF, CDKN2A, CTNNB1, DDR2, EGFR, ERBB2, FBXW7, FGFR1, FGFR2, FGFR3, HRAS, KEAP, KRAS, MAP2K1, MET, NOTCH1, NRAS, PIK3CA, POLE, PTEN, RET, SMAD4, SMARCA4, STK11, TP53
7 Gene rearrangements:
ALK, MET, ROS1, RET, NTRK1, NTRK2, NTRK3
Description: The test is designed for any type of solid tumor, providing information about the gene profile, using the non-invasive method of liquid biopsy. It is performed before choosing a treatment and for monitoring during treatment. It also helps to identify secondary mutations that could change the treatment plan.
Who is the Com.Pl.it DX® Liquid test suitable for?
• Patients with difficult-to-reach tumors and patients with little or no suitable tissue.
• Patients with multiple metastases.
• Patients undergoing treatment or after its completion.
How does the liquid biopsy test help in choosing a treatment plan or after it is completed?
• Determines the molecular profile of the tumor (gene mutations) and interactions between genes in cases of multiple mutations
• Identifies approved drugs targeting either the mutated genes or the pathways in which they are involved
• Identifies mutations associated with resistance to targeted therapies
• Recommends therapies outside of approved or clinical trial treatments. This may be especially important for patients in whom standard treatment has failed.
Deadline for receiving the result: 14 working days
Panel of 12 Gene Mutations:
ALK, BRAF, EGFR, ERBB2 KRAS, MAP2K1, MET, NRAS
PIK3CA, RET, ROS1, TP53
3 Gene rearrangements:
ALK, ROS1, RET
Description: The test is a powerful tool for assessing breast cancer status and can be used to decide whether a patient should undergo specific targeted treatment or not.
Com.Pl.it DX® Liquid Breast®:
• Determines the molecular profile of the tumor such as gene mutations and copy number variations for inoperable tumors.
• Indicates an approved drug targeting the mutated gene or the pathway in which the genes are involved.
• Identifies mutations associated with resistance to targeted treatment.
• Recommends therapies outside of approved and/or treatments included in clinical trials.
The Com.pl.it DX® Breast Fluid Test is suitable for:
• Patients with inoperable tumors and patients with limited or insufficient tissue biopsy material.
• Patients with multiple metastases.
• Patients on treatment or after completion of treatment. In this case, it provides insight into the possible emergence of new target mutations or mutations resistant to the therapy used
It is highly recommended for:
• Patients with difficult-to-access tumors and limited or insufficient tissue biopsy material
• Patients with multiple metastases
• Patients on treatment or after completion of treatment. In this case, it provides insight into the possible emergence of new target mutations or mutations resistant to the therapy used
10 Gene changes (approx. 152 hotspots):
AKT1, EGFR, ERBB2, ERBB3, ESR1, FBXW7, KRAS, PIK3CA, SF3B1, TP53
Changes in copy number:
CCND1, ERBB2, FGFR1
Full length genes:
TP53
In the gene panel above, we find mutations in the ESR1 gene (frequency 48% as a mechanism of resistance to hormonal therapy, based on the Emerald study).
We also find mutations in the PIK3CA gene with the approved treatment Alpelisib, as well as other genes for which there are experimental or off-label treatments.
Deadline for receiving the result: 14 working days
Inside all cells, there are protective caps called Telomeres at the ends of DNA. They shorten with age as they perform their function, i.e. while providing protection to genes and preventing cells from multiplying after they become old.
Longer telomeres indicate a better status of a person in terms of biological age, that is, such persons are biologically younger, more vital, regardless of their nominal age.
Short telomeres have been called the "new cholesterol" because decades of clinical research have shown that no matter how old you are, telomere length indicates your risk of heart disease and longevity in general.
The clinical significance of the telomere, in addition to the premature aging syndrome and diseases associated with it, is observed in the pathology of cancer, as well as in genetic anomalies. Recent studies have shown the prognostic significance of this biomarker as a biomarker of premature cell aging in vascular and metabolic diseases, neurodegenerative diseases, e.g. Alzheimer's and Parkinson's diseases, as well as arthritis and osteoporosis.
Telomere length is influenced by both genetic factors and environmental factors. Inflammation, hypertension, diabetes mellitus, obesity and excessive alcohol use contribute to telomere shortening.
The results of many studies confirm that oxidative stress (increased levels of pro-oxidants or impaired antioxidant protection mechanisms) also leads to a decrease in telomere length and thus leads to premature aging. Therefore, telomere length is a promising genetic marker for chronic oxidative stress.
Quality sleep, moderate physical activity, healthy diet (Mediterranean diet), appropriate supplementation, as well as psychosocial well-being lengthen telomeres, while insufficient number of hours of sleep, stress, smoking, lack of physical activity, caloric and fatty foods, too much sugar, shorten telomeres.
In order to know what your actual state of health is, as well as whether there are risks for the development of chronic diseases, as well as whether your supplementation is appropriate, we advise you to do an analysis to assess oxidative stress and telomere length. Based on them, long before any health problem manifests, it is possible to act and prevent the disease.
After receiving the results of the analyzes performed, personalized supplementation will be advised, and after 3 months the results will be repeated, in order to evaluate the effect of the therapy.
Patient preparation: no special preparation.
Time to get results: up to 30 days
Nowadays, maintaining health is a big challenge for every person. On the one hand, a large number of chemical compounds (food additives, pesticides, heavy metals, microplastics, etc.) in various ways lead to a weakening of immunity, and on the other hand, there is our great desire to apply everything that can contribute to restoring the balance of the organism. The essence of the problem lies in the fact that every organism is different, and living and working conditions are external factors that significantly contribute to and direct the organism's detoxification pathways.
In addition to this, various internal factors, such as: infections, inflammation, immunodeficiency, stress, aging, etc., have a significant negative impact on the development of oxidative stress and biological aging.
An imbalance between the capacity of antioxidant protection and the amount of free radicals created is the basis of the initial damage to healthy cells and the DNA chain in them, which further progression of the process leads to mitochondrial damage. The result of this process is the aging of the organism, the development of cardiovascular diseases, cancer, diabetes and many other chronic diseases. Today it is known that the described process of damage to cells by free radicals is reversible to such an extent that cells can be rejuvenated in 10-15 years. Thus, the probability of chronic diseases related to aging can be reduced.
To assess the possible lack of antioxidant protection, to assess your redox status, condition and disease progression, it is useful to do an oxidative stress panel. The obtained results are the basis for designing the content and dosage of the three-month preventive therapy with supplements.
The analysis includes the determination of 6 parameters, which give a clear picture of your:
Total antioxidant capacity Total Oxidative Potential Pro-oxidative - antioxidant balance Quantities of superoxide dismutase and reduced glutathione in erythrocytes.The results of the same analysis, after three months, will indicate the effect of the therapy, the possible need to correct the therapy and recommendations for changing lifestyle habits. The above results can be used for very early detection of the onset of the disease or for evaluating the effect of therapy.
Patient preparation: Blood sampling is recommended in the morning, after 12 hours of fasting.
Time to get results: up to 10 days.
Many scientists believe that a person lives as long as the organism is able to maintain the presence of glutathione in itself.
It is an important antioxidant, which neutralizes free radicals that are the cause of various diseases, gives us energy, better concentration and helps us react better to stress.
It rarely happens that glutathione deficiency is of a genetic nature, but it is important to know that its production in the body begins to decline from the age of 20, especially under various influences brought about by a modern lifestyle. A reduced level of glutathione in the body increases the risk of developing many diseases such as: diabetes, Parkinson's disease, hepatitis and various other infections.
Before applying any form of supplementation, we advise you to determine its concentration, so that your doctor can recommend adequate compensation, if necessary.
Preparation for analysis: 12 hours should pass since the last meal.
Results issuing: up to 10 days.
Chitotriosidase is an enzyme produced by activated macrophages and as such is a marker for inducing an immune response against various pathogens. The role of Chitotriosidase in modern laboratory diagnostics is very important, considering that it is considered the most specific biomarker of sarcoidosis, based on the activity of which the diagnosis is made along with the clinical picture and the effectiveness of the therapy is monitored. Chitotriosidase is used as a biomarker of disease severity, to differentiate disease activity and predict deterioration. In addition to sarcoidosis, chitotriosidase is used in the diagnosis of tuberculosis, asthma, interstitial lung disease, chronic obstructive disease, infections and other lung diseases.
Chitotriosidase is the most important marker of a group of rare diseases (lysosomal diseases), primarily Gaucher disease, in which, in addition to establishing a diagnosis, it is used to monitor the clinical picture and dose therapy. It is also determined in other rare metabolic diseases: Niemann-Pick disease, Fabry disease, Krabbe disease.
Increased chitotriosidase activity has also been found in various neurological diseases: amyotrophic lateral sclerosis, multiple sclerosis, stroke, Alzheimer's disease, cerebral adrenal leukodystrophy, cerebrovascular dementia and others. The enzyme is a significant marker of macrophage activity in atherosclerotic plaque and is related to the width and size of atherosclerotic lesions, and is used in the diagnosis of cardiovascular diseases (ischemic heart disease, coronary artery disease and strokes).
Chitotriosidase activity increases in patients with newly diagnosed type 2 diabetes mellitus, where it is a marker of accelerated atherosclerosis and correlates with the progression of nephropathy and retinopathy.
Considering that chitotriosidase is a marker of inflammatory response, it is of great importance in the diagnosis of infectious and parasitic diseases, especially candidiasis, malaria, leishmaniosis, toxoplasmosis, leprosy, brucellosis and others.
Significantly increased chitotriosidase activity also occurs in polycystic ovary syndrome (a state of low-grade chronic inflammation), where macrophage activity is associated with obesity, insulin resistance, and other metabolic disorders. Increased activity was also observed in endometriosis and preeclampsia.
In addition to the above, chitotriosidase is determined in the diagnosis of non-alcoholic fatty liver, ß-thalassemia, HBV and HCV hepatitis, various cancers and a large number of autoimmune diseases (SLE, Chron's disease, psoriasis, juvenile idiopathic arthritis and others).
It is determined in serum and cerebrospinal fluid.
Preparation: fasting for 12 hours.
Time of issue of results: 48h.